Drawing for ZUREXA

USPTO serial 76211309

ZUREXA

Reviewed by CopyMark Law Group

Status 605
Filing date
Status date
Registration date
Examiner
WONG, CONRAD
Law office
FILE REPOSITORY (FRANCONIA)

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ZUREXA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005PHARMACEUTICAL PREPARATIONS, FOR THE TREATMENT OF CARDIOVASCULAR DISEASES, CENTRAL NERVOUS SYSTEM DISEASES, CANCER, INFLAMMATION AND INFLAMMATORY DISEASES, RESPIRATORY AND INFECTIOUS DISEASES AND FOR DIAGNOSTIC IMAGINGACTIVE

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 14, 2003MAILPAPER RECEIVED
May 31, 2002ABN5ABANDONMENT - AFTER PUBLICATION
Jan 1, 2002NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Oct 9, 2001PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 19, 2001NPUBNOTICE OF PUBLICATION
Aug 17, 2001CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Jun 26, 2001DOCKASSIGNED TO EXAMINER
Jun 13, 2001DOCKASSIGNED TO EXAMINER

Frequently asked questions

Related guidance